Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 1 to 25 of 921

TitleReference numberPublishedLast updated
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)TA1180
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)TA1179
Deuruxolitinib for treating severe alopecia areataTA1178
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancerTA1177
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapyTA1174
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosisTA1175
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetesTA1176
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitorTA1173
Atogepant for treating migraineTA1172
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancerTA1169
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA1170
Seladelpar for previously treated primary biliary cholangitisTA1171
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA1167
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)TA1168
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTA1166
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1165
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentTA1164
Nusinersen and risdiplam for treating spinal muscular atrophyTA1162
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)TA1163
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatmentTA1159
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinomaTA1160
Sotatercept for treating pulmonary arterial hypertensionTA1161
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Givinostat for treating Duchenne muscular dystrophy in people 6 years and overTA1157

Results per page

  1. 10
  2. 25
  3. 50
  4. All